Three-Month Follow-Up of Heterologous vs. Homologous Third SARS-CoV-2 Vaccination in Kidney Transplant Recipients: Secondary Analysis of a Randomized Controlled Trial

Response to SARS-CoV-2-vaccines in kidney-transplant recipients (KTR) is severely reduced. Heterologous3rd vaccination combining mRNA and vector vaccines did not increase seroconversion at 4 weeks after vaccination, but evolution of antibody levels beyond the first month remains unknown. We have rec...

Full description

Bibliographic Details

Published in:	Frontiers in Medicine
Main Authors:	Andreas Heinzel, Eva Schrezenmeier, Florina Regele, Karin Hu, Lukas Raab, Michael Eder, Christof Aigner, Rhea Jabbour, Constantin Aschauer, Ana-Luisa Stefanski, Thomas Dörner, Klemens Budde, Roman Reindl-Schwaighofer, Rainer Oberbauer
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-07-01
Subjects:	COVID-19 kidney transplantation COVID-19 vaccination heterologous vaccination third vaccination
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2022.936126/full